Abstract
Metabolic response monitoring early during chemotherapy may have a major impact on clinical management of patients with malignant lymphoma. In two patients with non-Hodgkin's lymphoma fluorine-18 fluorodeoxyglucose (IgFDG) single-photon emission tomography (SPET) studies were performed during the first two chemotherapeutic cycles. Persisting uptake predicted treatment failure whereas a sharp reduction of 18FDG uptake was demonstrated in the case of a responsive tumour. Qualitative analysis of conventional 18FDG imaging may thus serve to identify patients with a non-responding tumour. The potential of this technique in the determination of the initial response remains to be established. Imaging with 18FDG and SPET appears promising as a more easily available methodology than 18FDG positron emission tomography.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kostakoglu L, Yeh SDJ, Portlock C, et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992;33: 345–351.
Stomper PC, Cholewinski SP, Park J, et al. Abdominal staging of thoracic Hodgkin's disease: CT-lymphangiography-Ga-67 scanning correlation. Radiology 1993;187: 381–386.
Wylie BR. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 1989;42: 344–347.
Jochelson M. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985;5: 637–640.
Surbone A, Longo DL, DeVita Jr VT, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol 1988;6: 1832–1837.
Levis A, Vitolo U, Ciocca Vasino MA, et al. Predictive value of the early response to chemotherapy in high-risk stages I and II Hodkin's disease. Cancer 1987;60: 1713–1719.
Armitage JO, Weisenburger DD, Hutchins M, et al. Chemotherapy for DLCL-rapidly responding patients have more durable remissions. J Clin Oncol 1986;4: 160–164.
Royal HD. Clinical applications of positron emission tomography in cancer: the good, the bad and the ugly. J Nucl Med 1992;33: 330–332.
Armitage JO, Cheson BD. Interpretaton of clinical trials in DLCL. J Clin Oncol 1988;6: 1335–1347.
Surbone A, Armitage JO, Gale RP. Autotransplantation in lymphoma: better therapy or healthier patients? Ann Intern Med 1991;14:1059–1060.
Coiffier B, Gisselbrecht C. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. J Clin Oncol 1991;9: 211–219.
Van Lingen A, Huijgens PC, Visser FC, et al. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma camera. Eur J Nucl Med 1992;19: 315–321.
Paul R. Comparison of fluorine-18–2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987;28: 288–292.
Hoekstra OS, Golding R, Ossenkoppele GJ, et al. Early treatment response in malignant lymphoma, as determined by planar 18F-fluorodeoxyglucose scintigraphy. J Nucl Med (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoekstra, O.S., van Lingen, A., Ossenkoppele, G.J. et al. Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography. Eur J Nucl Med 20, 1214–1217 (1993). https://doi.org/10.1007/BF00171020
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00171020